News | June 23, 2021
Sun Pharma settles patent litigation for Revlimid
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
These five oxygen plants with a total capacity of 3,840 cubic meters of oxygen per day have been donated to Madhya Pradesh, Maharashtra, and Gujarat
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Aurobindo has one of the most enduring generics ecosystems among peers
Subscribe To Our Newsletter & Stay Updated
